Suppr超能文献

皮质类固醇诱导的神经精神效应的分子、病理生理及临床方面:从实验台到病床

Molecular, Pathophysiological, and Clinical Aspects of Corticosteroid-Induced Neuropsychiatric Effects: From Bench to Bedside.

作者信息

Sofía-Avendaño-Lopez Sara, Rodríguez-Marín Angela Johanna, Lara-Castillo Mateo, Agresott-Carrillo Juanita, Lara-Cortés Luna Estefanía, Sánchez-Almanzar Juan Felipe, Villamil-Cruz Sophya, Rojas-Rodríguez Luis Carlos, Ariza-Salamanca Daniel Felipe, Gaviria-Carrillo Mariana, Calderon-Ospina Carlos Alberto, Rodríguez-Quintana Jesús

机构信息

Social Epidemiology Research Team, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Sorbonne Université, F 75012 Paris, France.

Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 111221, Colombia.

出版信息

Biomedicines. 2024 Sep 19;12(9):2131. doi: 10.3390/biomedicines12092131.

Abstract

Corticosteroids are frequently prescribed across medical disciplines, yet they are associated with various adverse effects, including neuropsychiatric symptoms, documented since their introduction over 60 years ago. The cellular mechanisms underlying neuropsychiatric symptoms are complex and somewhat obscure, involving multiple pathways. Notably, they include changes in excitability, cellular death of hippocampal and striatal neurons, and increased inflammation and oxidative stress. Clinical presentation varies, encompassing affective disorders (anxiety, euphoria, depression), psychotic episodes, and cognitive deficits. It is crucial to note that these manifestations often go unnoticed by treating physicians, leading to delayed detection of severe symptoms, complications, and underreporting. Discontinuation of corticosteroids constitutes the cornerstone of treatment, resolving symptoms in up to 80% of cases. Although the literature on this topic is scant, isolated cases and limited studies have explored the efficacy of psychotropic medications for symptomatic control and prophylaxis. Pharmacological intervention may be warranted in situations where corticosteroid reduction or withdrawal is not feasible or beneficial for the patient.

摘要

皮质类固醇在各医学学科中都经常被处方使用,但自60多年前引入以来,它们就与各种不良反应相关,包括神经精神症状。神经精神症状背后的细胞机制复杂且有些模糊,涉及多条途径。值得注意的是,这些机制包括兴奋性变化、海马体和纹状体神经元的细胞死亡,以及炎症和氧化应激增加。临床表现各不相同,包括情感障碍(焦虑、欣快感、抑郁)、精神病发作和认知缺陷。需要注意的是,这些表现往往未被治疗医生注意到,导致严重症状、并发症的检测延迟以及报告不足。停用皮质类固醇是治疗的基石,在高达80%的病例中可缓解症状。尽管关于这一主题的文献很少,但个别病例和有限的研究已经探讨了精神药物对症控制和预防的疗效。在无法减少或停用皮质类固醇或对患者无益的情况下,可能有必要进行药物干预。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91f7/11429036/92c772491185/biomedicines-12-02131-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验